CA-INSEEGO-CORP
9.2.2021 15:02:10 CET | Business Wire | Press release
Inseego Corp. (Nasdaq: INSG), a leader in 5G and intelligent IoT device-to-cloud solutions, today announced that its new Wavemaker PRO 5G indoor router has been certified for use in Europe, North America* and Australia, with additional regulatory certifications pending for other international markets. Designed specifically for enterprise customers, this router combines high-performance, multi-carrier 5G and Wi-Fi 6 connectivity with cloud software that simplifies device management, maximizes security and minimizes expenses for enterprise users.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210209005447/en/
“Our Wavemaker PRO 5G solutions are changing the way enterprise and SMB customers think about broadband access,” said Inseego President Ashish Sharma. “Whether they have remote branch offices needing faster primary communications, retail locations needing failover solutions, or a distributed workforce needing dependable and secure work-from-home access to their corporate network, the FG2000e router can deliver unmatched speed, throughput and reliability — along with software solutions that make it easy for IT organizations to deploy and manage their devices, protect their networks, and reap the benefits of a multi-carrier 5G managed WAN.”
Bringing 5G enterprise solutions to global markets
The Wavemaker PRO 5G indoor router FG2000e has now received industry certifications that make it commercially available for deployments in many global markets. It’s important to understand that different countries and regions require different types of regulatory and 3GPP certifications in order to operate 5G products on mobile networks. For example, GCF certification demonstrates that products conform with 3GPP standards and will be interoperable with mobile networks worldwide. CE certification means that solutions can be sold to service providers and enterprise customers in over 30 countries of the European Economic Area (EEA) and European Free Trade Association (EFTA). RCM certification verifies that electrical and wireless equipment can be sold in Australia. And FCC certification requires a rigorous process of testing before RF products can be sold and marketed in the U.S.
Having completed all of these certifications, the FG2000e router can now be sold to service providers and enterprise customers across all of these regions, including organizations that are deploying 5G private networks.
New global channel partners
In addition to partnering with service providers, Inseego is expanding its network of distributors, resellers and system integrators worldwide to create new channels to market, along with local market support for its new enterprise solutions. The FG2000e router and software provides local language support, including English, French, Italian, Spanish, German, Arabic and Japanese.
A multi-carrier 5G cloud managed WAN for ubiquitous broadband connectivity
The Wavemaker PRO 5G indoor router FG2000e provides high-performance 5G connectivity and 4G LTE fallback, with features such as:
- Unlocked, dual-SIM, multi-carrier firmware that provides flexibility and ultimate control of the network the router connects to, avoiding downtime and data usage overage charges
- Centralized cloud management through the Inseego Manage ™ cloud solution, which simplifies device configuration, installation, remote management, security and support, providing an excellent customer experience right “out of the box” and for the full product lifecycle
- Enterprise-grade security that includes WPA3 Wi-Fi security support, advanced encryption, Open VPN and IPsec VPN
- Added value with a robust pipeline of new features including WAN management, enterprise security, device management and vertical market applications.
The Wavemaker PRO 5G indoor router FG2000e can deliver gigabit-plus speeds (using sub-6 GHz 5G) that match or outperform typical cable and fiber optic speeds. The FG2000e is ideal for business offices, retail locations, medical facilities, campuses and remote job sites needing reliable, high-speed broadband access with features such as:
- A 5 Gbps ethernet port, additional LAN and WAN ports, and TS9 port for external antenna
- Wi-Fi 6 technology to support up to 128 Wi-Fi-enabled devices
- An RJ-11 port for optional Voice over LTE (VoLTE)
5G for private networks
According to IDC , the private LTE/5G equipment market will reach $5.7 Billion in 2024. “With more spectrum being made available for enterprise uses, coinciding with the arrival of commercial 5G, interest has grown toward using private LTE/5G solutions as a basis for connectivity across a multitude of mission-critical, industrial and traditional enterprise organizations.”
Inseego 5G: Fast, reliable and secure
Designed and developed in the U.S., Inseego 5G products deliver high speed and low latency with extensive cybersecurity, including WPA3 Wi-Fi security with advanced encryption, Open VPN, IPsec VPN, parental controls and more.
To learn more about Inseego 5G products and solutions go to inseego.com . For press and analyst inquires, please email press@inseego.com
* Pending carrier approval.
About Inseego Corp.
Inseego Corp. (Nasdaq: INSG) is an industry leader in smart device-to-cloud solutions that extend the 5G network edge, enabling broader 5G coverage, multi-gigabit data speeds, low latency and strong security to deliver highly reliable internet access. Our innovative mobile broadband, fixed wireless access (FWA) solutions, and software platform incorporate the most advanced technologies (including 5G, 4G LTE, Wi-Fi 6 and others) into a wide range of products that provide robust connectivity indoors, outdoors and in the harshest industrial environments.
Designed and developed in the USA, Inseego products and SaaS solutions build on the company’s patented technologies to provide the highest quality wireless connectivity for service providers, enterprises, and government entities worldwide. www.inseego.com #Putting5GtoWork
©2021 Inseego Corp. All rights reserved. The Inseego name and logo are registered trademarks, and the Wavemaker and Inseego Manage names are trademarks of Inseego Corp. Other Company, product or service names mentioned herein are the trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210209005447/en/
Link:
Social Media:
https://www.facebook.com/Inseego/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom